Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini, Daniela Sia, Nabeel Bardeesy, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 2, pp. 291-300
Closed Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1722
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1009
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 328
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Demetrios Moris, Manisha Palta, Charles Kim, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 2, pp. 198-222
Open Access | Times Cited: 282
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Alphonse E. Sirica, Gregory J. Gores, John D. Groopman, et al.
Hepatology (2018) Vol. 69, Iss. 4, pp. 1803-1815
Open Access | Times Cited: 273
Molecular Pathogenesis of Cholangiocarcinoma
Peter Labib, George Goodchild, Stephen P. Pereira
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 255
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Robert Montal, Daniela Sia, Carla Montironi, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 315-327
Open Access | Times Cited: 219
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub, Nishanth S. Iyengar, Siddhant Dogra, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 215
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Kun Cheng, Ning Cai, Jinghan Zhu, et al.
Cancer Communications (2022) Vol. 42, Iss. 11, pp. 1112-1140
Open Access | Times Cited: 215
ROS1-dependent cancers — biology, diagnostics and therapeutics
Alexander Drilon, Chelsea Jenkins, Sudarshan R. Iyer, et al.
Nature Reviews Clinical Oncology (2020) Vol. 18, Iss. 1, pp. 35-55
Open Access | Times Cited: 210
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription
Qinjunjie Chen, Haibo Wang, Zheng Li, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 135-147
Open Access | Times Cited: 172
Combined hepatocellular-cholangiocarcinoma: An update
Aurélie Beaufrère, Julien Caldéraro, Valérie Paradis
Journal of Hepatology (2021) Vol. 74, Iss. 5, pp. 1212-1224
Open Access | Times Cited: 148
Current and emerging therapies for advanced biliary tract cancers
Audrey E. Kam, Ashiq Masood, Rachna T. Shroff
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 956-969
Closed Access | Times Cited: 120
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Alessandra Elvevi, Alice Laffusa, Miki Scaravaglio, et al.
Annals of Hepatology (2022) Vol. 27, Iss. 5, pp. 100737-100737
Open Access | Times Cited: 92
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity
Agrin Moeini, Daniela Sia, Zhongyang Zhang, et al.
Journal of Hepatology (2017) Vol. 66, Iss. 5, pp. 952-961
Open Access | Times Cited: 158
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
Loïc Verlingue, David Malka, Adrien Allorant, et al.
European Journal of Cancer (2017) Vol. 87, pp. 122-130
Closed Access | Times Cited: 155
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Germana Castelli, Elvira Pelosi, Ugo Testa
Cancers (2017) Vol. 9, Iss. 9, pp. 127-127
Open Access | Times Cited: 144
Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
Chirag Nepal, Colm J. O’Rourke, Douglas V.N.P. Oliveira, et al.
Hepatology (2017) Vol. 68, Iss. 3, pp. 949-963
Open Access | Times Cited: 122
Chemoresistance and chemosensitization in cholangiocarcinoma
José J.G. Marı́n, Elisa Lozano, Elisa Herráez, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2017) Vol. 1864, Iss. 4, pp. 1444-1453
Closed Access | Times Cited: 116
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
Weijing Sun, Anuj Patel, Daniel P. Normolle, et al.
Cancer (2018) Vol. 125, Iss. 6, pp. 902-909
Open Access | Times Cited: 111
Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas
Masayuki Akita, Kohei Fujikura, Tetsuo Ajiki, et al.
Modern Pathology (2017) Vol. 30, Iss. 7, pp. 986-997
Open Access | Times Cited: 110
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers
Soo Young Cho, Jun Won Park, Yang Liu, et al.
Gastroenterology (2017) Vol. 153, Iss. 2, pp. 536-549.e26
Open Access | Times Cited: 108
Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma
Zhuoxian Rong, Zhi Li, Junju He, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 108
Pathogenesis of Cholangiocarcinoma
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, et al.
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 433-463
Open Access | Times Cited: 108
MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma
Andrea Lampis, Pietro Carotenuto, Georgios Vlachogiannis, et al.
Gastroenterology (2017) Vol. 154, Iss. 4, pp. 1066-1079.e5
Open Access | Times Cited: 106
Page 1 - Next Page

Scroll to top